| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Abaxis has a current Overall Rating of A (Highest Rating). | 7 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ABAXIS INC (ABAX=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ABAXIS INC (ABAX=US) 12-months forecast | 1 |
$15 |
| 27-Nov-2009 | Validea |
N/A
| Validea Guru Analysis Report for ABAX. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others. | 0 |
$18 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for MEDICAL SUPPLIES | 18 |
$49 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| ABAX: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | ABAXIS INC (ABAX=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for ABAX | 13 |
$25 |
1.48% Nasdaq 
Research Reports
